New Technique Allows Noninvasive Tracking of Stem Cells in the Brain
Article ID: 574719
Released: 24-Mar-2011 11:00 AM EDT
Source Newsroom: Wolters Kluwer Health: Lippincott Williams and Wilkins
Fluorescence from 'Quantum Dots' Can Be Monitored Through the Skull, Reports Neurosurgery
Newswise — Philadelphia, Pa. (March 24, 2011) – A new technique using "quantum dots" produced through nanotechnology is a promising approach to monitoring the effects of stem cell therapies for stroke and other types of brain damage, reports the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
The researchers report the successful use of "near-infrared fluorescence labeling" to track the behavior of injected stem cells in brain-injured rats. "The results open up new opportunities to develop non-invasive near-infrared fluorescence imaging…to track bone marrow stem cells transplanted into the human brain," write Dr. Taku Sugiyama and colleagues of Hokkaido University Graduate School of Medicine, Sapporo, Japan. Quantum Dots Allow Monitoring of Stem Cell Therapy for Brain InjuryThe researchers used bone marrow stem cells to treat induced brain injuries, similar to stroke, in rats. Before injection, the stem cells were labeled with "quantum dots"—a biocompatible, fluorescent semiconductor created using nanotechnology.
Other fluorescence techniques used to label stem cells have an important limitation—their relatively short wavelengths don't easily penetrate through bone and skin. The quantum dots emit near-infrared light, with much longer wavelengths that can easily penetrate tissues. This allowed the researchers to monitor the behavior of stem cells within the brain after transplantation using a computer-assisted 3-D imaging system.
Using this technology, Dr. Sugiyama and colleagues were able to detect near-infrared fluorescence from the stem cells as they moved to and incorporated themselves into the area around the injured area of the brain. Reflecting the stem cells' behavior, the fluorescence increased gradually, peaking at four weeks after injection.
The fluorescence remained detectable for up to eight weeks. The findings were confirmed by direct examination of the brains.
Stem cell transplantation is a potentially valuable treatment for stroke and other central nervous system disorders. The use of stem cells developed from the patient's own bone marrow is a particularly promising approach. For example, a study in the March issue of Neurosurgery reported that bone marrow stem cell transplantation was a "logistically feasible and safe" approach to treatment of severe traumatic brain injury in children.
However, some type of imaging system is needed to monitor the activity of stem cells as they travel to the injured area and develop into new brain cells. "Such techniques would be crucial to validate the therapeutic benefits of bone marrow stem cell transplantation for central nervous system disorders," Dr. Sugiyama and coauthors write.
Near-infrared fluorescence labeling using quantum dots appears to provide a noninvasive technique for monitoring the effects of stem cell transplantation in the rat brain. Further research will be needed to see if similar techniques can be developed and used in humans. If so, this technology would be an important part of experimental stem cell therapies to promote functional recovery of the brain after stroke or other types of injury.
About NeurosurgeryNeurosurgery, the Official Journal of the Congress of Neurological Surgeons, is your most complete window to the contemporary field of neurosurgery. Members of the Congress and non-member subscribers receive 3,000 pages per year packed with the very latest science, technology, and medicine, not to mention full-text online access to the world's most complete, up-to-the-minute neurosurgery resource. For professionals aware of the rapid pace of developments in the field, Neurosurgery is nothing short of indispensable.
About Lippincott Williams & Wilkins Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services.
LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health and pharmacy. Major brands include traditional publishers of medical and drug reference tools, journals, and textbooks, such as Lippincott Williams & Wilkins and ; and electronic information providers, such as Ovid®, UpToDate®, Medi-Span®, Facts & Comparisons®, and ProVation® Medical.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company focused on professionals with annual revenues (2009) of €3.4 billion ($4.8 billion), approximately 19,300 employees worldwide and operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Visit our website, YouTube or follow @Wolters_Kluwer on Twitter for more information about our market positions, customers, brands and organization.